Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Cash & Equivalents (2016 - 2025)

OptimizeRx's Cash & Equivalents history spans 16 years, with the latest figure at $19.5 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 21.04% year-over-year to $19.5 million; the TTM value through Sep 2025 reached $19.5 million, up 21.04%, while the annual FY2024 figure was $13.4 million, 3.41% down from the prior year.
  • Cash & Equivalents for Q3 2025 was $19.5 million at OptimizeRx, up from $16.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $89.0 million in Q1 2022 and bottomed at $9.8 million in Q2 2023.
  • The 5-year median for Cash & Equivalents is $16.6 million (2025), against an average of $38.6 million.
  • The largest annual shift saw Cash & Equivalents surged 705.21% in 2021 before it crashed 88.78% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $84.7 million in 2021, then tumbled by 78.5% to $18.2 million in 2022, then decreased by 23.93% to $13.9 million in 2023, then dropped by 3.41% to $13.4 million in 2024, then skyrocketed by 45.88% to $19.5 million in 2025.
  • Per Business Quant, the three most recent readings for OPRX's Cash & Equivalents are $19.5 million (Q3 2025), $16.6 million (Q2 2025), and $16.6 million (Q1 2025).